Chimerism analysis and BCR/ABL minimal residual disease detection in bone marrow (BM) or peripheral blood (PBL) from the patient after treatment with leukemia-reactive CTL. Cells of donor (HS) origin could be detected by AFP polymorphism (heterozygous 145- and 72-bp fragments); cells of patient (KG) origin could be detected by NGF-β polymorphism (heterozygous for 100- and 50-bp fragments). (A) Between days 70 and 105 after the first CTL infusion, chimerism of MNC in BM and PBL completely converted to donor origin. (B) PMN from the patient were completely of donor origin from day 105 (5 weeks after the last CTL infusion). (C) Complete molecular remission was documented at day 140, 10 weeks after the last CTL infusion by disappearance of the patient b2a2 BCR/ABL transcript. C1, control b3a2 cDNA; C2, control b2a2 cDNA; N, negative control. RT-PCR of the HPRT gene served as an internal control for cDNA synthesis.